Prescient Therapeutics granted U.S. Patents

THE ROADHOUSE PHARMACY: Prescient Therapeutics (ASX: PTX) has had two additional patents granted by the U.S Patent and Trademark Office.

The company said the patents are important in the development and commercialisation of its drug candidate PTX-200.

The first patent provides broad protection for the company’s novel method of treating chemotherapy resistant ovarian cancer with the AKT inhibitor compound PTX-200, formerly known as TCN-P or triciribine phosphate monohydrate.

The second patent provides broad coverage for treating various cancer types including breast cancer by administering PTX-200 in combination with trastuzumab.

“These U.S. patents further enhance our intellectual property portfolio,” Prescient Therapeutics managing director Dr Robert Crombie said in the company’s announcement to the Australian Securities Exchange.

“They confirm our monopoly rights on this novel and highly encouraging compound which we believe has significant potential to improve the clinical outcome for women with chemotherapy-resistant ovarian cancer.

“Prescient’s drug candidate PTX-200 is being trialled in patients who have become resistant to platinum-based drugs as it inhibits the AKT tumor survival pathway associated with platinum drug resistance PTX-200, in combination with standard of care drug carboplatin, is currently in Phase 1b/2 trial as a new therapy for ovarian cancer, the fifth leading cause of cancer death in women in the United States.

“Currently approximately half of the patients diagnosed with ovarian cancer will die from metastatic disease as they become resistant to the platinum-based drugs that constitute front line therapy.

“Prescient’s drug candidate PTX-200 is aiming to minimise this resistance.”

Website: www.prescienttherapeutics.com